Sun Pharmaceutical Industries has reported the financials for the first quarter ending June 30, 2021. In Q1FY22, the consolidated sales from operations at Rs 96,694 million, a growth of 29 per cent over Q1 last year and 14 per cent over Q4 last year. India sales have been reported at Rs 33,084 million, up 39 per cent compared to Q1 last year. The US finished dosage sales at $380 million, a growth of 35 per cent over the same quarter last year. The Emerging Markets sales was at $218 million, up by 25 per cent over Q1 last year. The Rest of World sales was at $185 million, up by 35 per cent over Q1 last year. 

The R&D investments are at Rs 5,926 million compared to Rs 4,206 million for Q1FY21. EBITDA at Rs 27,718 million, up by 59 per cent over Q1 last year, with a resulting EBITDA margin of 28.7 per cent. The adjusted net profit for the quarter was at Rs 19,792 million, up by 73 per cent YoY, after excluding the exceptional items of Rs. 6,311 million and relevant minority interest of Rs. 960 million. The adjusted net profit margin at 20.5 per cent compared to 15.3 per cent for Q1 last year. The company reported a net profit for Q1FY22 was at Rs 14,442 million. 

Dilip Shanghvi, MD, Sun Pharma said, “We witnessed a strong Q1, driven by a combination of robust core business growth, low base and some sale of Covid products. We are enthused by the all-around growth across all our businesses compared to Q4 last year. Our India business continues to do well while our global speciality revenues have grown over Q4. We are happy with Ilumya’s performance which has grown both YoY and sequentially. We continue to focus on growing our overall business and simultaneously strengthening our global speciality portfolio. The recent in-licensing of Winlevi for the US and Canada is a step forward in this direction.”